(R)-2-(4-Methoxy-benzenesulfonylamino)-3-phenyl-propionic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-2-(4-Methoxy-benzenesulfonylamino)-3-phenyl-propionic acid
• 英文别名: (2R)-2-{[(4-methoxyphenyl)sulfonyl]amino}-3-phenylpropanoic acid；(2R)-2-[(4-methoxyphenyl)sulfonylamino]-3-phenylpropanoic acid
• 化学式: C₁₆H₁₇NO₅S
• 分子量: 335.381
• InChiKey: DBKQRNHRAQHJGB-OAHLLOKOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  23
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (R)-2-(4-Methoxy-benzenesulfonylamino)-3-phenyl-propionic acid 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 51.0h， 生成 (R)-2-[Benzyl-(4-methoxy-benzenesulfonyl)-amino]-3-phenyl-propionic acid tert-butyl ester
  参考文献：
  名称：

  Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits

  摘要：

  Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.

  DOI：

  10.1021/jm960871c
• 作为产物：
  描述：

  D-苯丙氨酸 、 对甲氧基苯磺酰氯 在 三乙胺 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 (R)-2-(4-Methoxy-benzenesulfonylamino)-3-phenyl-propionic acid
  参考文献：
  名称：

  Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits

  摘要：

  Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.

  DOI：

  10.1021/jm960871c

文献信息

• [EN] SMALL MOLECULE DIRECT INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION<br/>[FR] INHIBITEURS DIRECTS À PETITES MOLÉCULES D'INTERACTION PROTÉINE-PROTÉINE DE KEAP1-NRF2
  申请人：UNIV RUTGERS

  公开号：WO2020150446A1

  公开（公告）日：2020-07-23

  This patent document diclsoes novel compounds and methods of preventing or treating diseases or conditions related to Keapl-Nrf2 interaction activity by use of the novel compounds. As direct inhibitors of Keapl-Nrf2 interaction, the compounds disclosed herein are more specific and free of various undesirable effects than existing indirect inhibitors, and are potential dmg candidates of chemopreventive and therapeutic agents for treatment of various diseases or conditions involving oxidative stress and/or inflammation, including but not limited to cancers, diabetes, Alzheimer's, Parkinson's, and inflammatory bowel disease including ulcerative colitis.

  这项专利文件披露了一种新颖的化合物和方法，通过使用这些新颖的化合物来预防或治疗与Keapl-Nrf2相互作用活性相关的疾病或状况。作为Keapl-Nrf2相互作用的直接抑制剂，本文披露的化合物比现有的间接抑制剂更具特异性，且不受各种不良影响，是潜在的化学预防和治疗剂的候选人，用于治疗涉及氧化应激和/或炎症的各种疾病或状况，包括但不限于癌症、糖尿病、阿尔茨海默病、帕金森病和溃疡性结肠炎等。
• Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits
  作者：Lawrence J. MacPherson、Erol K. Bayburt、Michael P. Capparelli、Brian J. Carroll、Robert Goldstein、Michael R. Justice、Lijuan Zhu、Shou-ih Hu、Richard A. Melton、Lynn Fryer、Ron L. Goldberg、John R. Doughty、Salvatore Spirito、Vincent Blancuzzi、Doug Wilson、Elizabeth M. O'Byrne、Vishwas Ganu、David T. Parker

  DOI：10.1021/jm960871c

  日期：1997.8.1

  Structure-activity relationships of a lead hydroxamic acid inhibitor of recombinant human stromelysin were systematically defined by taking advantage of a concise synthesis that allowed diverse functionality to be explored at each position in a template. An ex vivo rat model and an in vivo rabbit model of stromelysin-induced cartilage degradation were used to further optimize these analogs for oral activity and duration of action. The culmination of these modifications resulted in CGS 27023A, a potent, orally active stromelysin inhibitor that blocks the erosion of cartilage matrix.